NCT06947473View on ClinicalTrials.gov

Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 18, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

July 31, 2026

Conditions
Refractory Lupus NephritisSystemic SclerosisPrimary Sjogren's Syndrome Combined With Pulmonary Hypertension
Interventions
DRUG

umbilical cord blood CD19-BCMA CAR-T cells infusion

Approximately 3-5 days prior to umbilical cord blood CD19-BCMA CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.

All Listed Sponsors
lead

Beijing GoBroad Hospital

OTHER